NCT01288222

Selecting a Favorable KIR Donor in Unrelated HCT for AML

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 506 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically, donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect. This study proposes to prospectively test and validate the utility and effectiveness of further informing URD identification and selection by KIR genotyping as a supplement to HLA matching and the other variables known or suspected to indicate the best URD for a patient. Hypotheses: 1. Favorable KIR donors will improve protection against relapse and improve leukemia free survival (LFS) after URD HCT for AML. 2. Directed study procedures for rapid KIR genotyping and reporting to searching Transplant Centers (TC) can inform donor search and selection without delay in donor availability for HCT.

Detailed description

Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor.

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
OTHER	KIR genotype	KIR genotype data from unrelated donor are collected

Timeline

• Start date: 2011-06-01
• Primary completion: 2020-04-01
• Completion: 2020-04-01
• First posted: 2011-02-02
• Last updated: 2021-03-11

Locations

19 sites across 1 country: United States